Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme

Gondos, Ádám; Krilavičiūtė, Agnė; Smailytė, Giedrė; Ulys, Albertas; Brenner, Hermann

doi:10.1016/j.ejca.2015.04.009

Cited by 24 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no reduction in prostate cancer risk among men with T2DM in our study, in contrast to a recent meta-analysis, which showed a decreased risk of prostate cancer in diabetic men (RR 0.86, 95% CI 0.80-0.92) [25]. In Lithuania an official nationwide prostate cancer early detection program was introduced in 2006, resulting in subsequent prostate cancer incidence peaks [26]. Therefore, obtained risk excess of prostate cancer in our study group could in part be explained by surveillance bias since patients with diabetes are under increased surveillance and are more likely to undergo additional medical examinations including prostate-specific antigen (PSA) testing.…”

Section: Discussioncontrasting

confidence: 98%

Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study

Linkeviciute-Ulinskiene

Patašius

Zabulienė

et al. 2019

IJERPH

Self Cite

View full text Add to dashboard Cite

A retrospective cohort design was used with the objective to evaluate cancer risk among people with type 2 diabetes mellitus (T2DM) in Lithuania. The cohort was established by identifying all patients with the first diagnosis of T2DM in the National Health Insurance Fund database during 2000-2012. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry. Standardized incidence ratios (SIRs) were calculated. Of the 127,290 people that were included, 5959 cases of cancer in men and 6661 cancer cases in women with T2DM were observed. A statistically significant increase in risk for all cancer sites was observed in women, SIR 1.16 (95% CI 1.14-1.19), but not in men, SIR 1.00 (95% CI 0.98-1.03). Among males, a significant increase of liver (SIR 2.11, 95% CI 1.79-2.49]), pancreas (SIR 1.77, 95% CI 1.57-1.99), kidney (SIR 1.46 95% CI 1.31-1.62), thyroid (SIR 1.83, 95% CI 1.32-2.54), colorectal (SIR 1.23, 95% CI 1.14-1.31]), skin melanoma (SIR 1.40, 95% CI 1.11-1.76), and non-melanoma skin (SIR 1.14, 95% CI 1.05-1.23) cancer was observed. For females with T2DM, a significant increase in risk of cancer of the liver (SIR 1.45, 95% CI 1.17-1.79), pancreas (SIR 1.74, 95% CI 1.56-1.93), kidney (SIR = 1.43, 95% CI 1.28-1.60), thyroid (SIR = 1.40, 95% CI 1.22-1.62), breast (SIR = 1.24, 95% CI 1.17-1.31), and corpus uteri (SIR 2.07, 95% CI 1.93-2.21) was observed. In conclusion, people with T2DM in Lithuania had an increased risk of site-specific cancer.

show abstract

Section: Discussioncontrasting

confidence: 98%

Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study

Linkeviciute-Ulinskiene

Patašius

Zabulienė

et al. 2019

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…The American Urological Association (AUA) recommends shared decision making for men age 55–69 that are considering PSA screening . To date, Lithuania is the only country with a nation‐wide screening programme . However, in many countries there is widespread opportunistic screening since >10–20 years, especially at older ages .…”

Section: Advantageous Protocolmentioning

confidence: 99%

“…28 To date, Lithuania is the only country with a nation-wide screening programme. 29 However, in many countries there is widespread opportunistic screening since >10-20 years, especially at older ages. 30,31 For example in Stockholm, 25% of the men aged 50-59 had a PSA test, increasing to 46% at age 70-79 in the period 2010-2011.…”

Section: Cancer Epidemiologymentioning

confidence: 99%

Summary statement on screening for prostate cancer in Europe

Heijnsdijk¹,

Bangma

Borrás

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that Prostate-Specific Antigen (PSA) based screening results in a significant prostate cancer mortality reduction. Although there are concerns on overdiagnosis and overtreatment, it has been shown that the benefits can outweigh the harms if screening is stopped in older ages to prevent overdiagnosis. A limited screening program (for example screening at ages 55-59 years), including active surveillance for men with low-risk tumors, can even be cost-saving, compared with testing in an opportunistic setting in the wrong ages, as currently in Europe. Further improvements are expected in the use of active surveillance and in discrimination between indolent and significant disease due to new biomarkers and magnetic resonance imaging. However, these future developments are no reason to postpone feasibility studies of high-quality PSA screening and reduce opportunistic testing at old ages.

show abstract

“…7,10 Out of all European countries, Lithuania had the highest rate of mortality at 36 per 100,000. 4,10 Norway had the fifth highest mortality rate from prostate cancer among European countries.…”

Section: High Income Country Prostate Cancer Epidemiologymentioning

confidence: 99%

“…Prostate cancer is a disease that is becoming an important public health concern worldwide. [1][2][3][4][5][6] According to the World Health Organization, in 2012, prostate cancer was the second most common cause of cancer in men and fourth most cause of cancer in both genders worldwide. [7][8][9] Among male cancers unrelated to the skin, prostate cancer is the most common cause of cancer in the Western world.…”

Section: Introductionmentioning

confidence: 99%

Worldwide Prostate Cancer Epidemiology: Differences Between Regions, Races, and Awareness Programs

Banerjee¹,

Kaviani²

2016

IJCEMS

View full text Add to dashboard Cite

Prostate cancer, according to the World Health Organization, is the second most common cause of cancer worldwide. With an estimated 1.1 million people affected by prostate cancer in 2012, composing 15% of all new cancer cases worldwide, this condition poses a significant burden of mortality and morbidity on society. Even though the burden of prostate cancer is present worldwide, there are disparities in mortality rates worldwide. While in Sub-Saharan Africa and Caribbean, the age-adjusted mortality rates are as high as 24 per 100,000, in Asia the age-adjusted mortality rates are as low 2.9 per 100,000. Specific countries in Sub-Saharan Africa like Uganda have a prostate cancer mortality rate as high as 38.8 per 100,000, which is close to the incidence rate of 48.2 per 100,000. Even though in the United Kingdom the incidence rate is much higher at 111.1 per 100,000, the mortality rate is comparable to that of Sub-Saharan Africa at 22.8 per 100,000. As demonstrated in this global review of prostate cancer, the age-adjusted incidence rate and mortality rate are closer together in Sub-Saharan Africa than in high income countries. Also, there are disparities in age-adjusted mortality rates of prostate cancer. There is plausibly a large gap in data on incidence and mortality rates of prostate cancer, leading to potential underreporting of incidence rates. There are also different awareness related gaps in developing and developed countries. Improved surveillance systems need to be established in order to improve early detection screening programs and prioritized interventions for evidence-based policy for prostate cancer in all countries.

show abstract

Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme

Cited by 24 publications

References 32 publications

Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study

Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study

Summary statement on screening for prostate cancer in Europe

Worldwide Prostate Cancer Epidemiology: Differences Between Regions, Races, and Awareness Programs

Contact Info

Product

Resources

About